← Eichor
Condition: Nk Cell Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Nk Cell

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Phase 1 · 1 location(s) · Beijing Biotech · NCT07480941NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Phase 2 · 13 location(s) · New Approaches to Neuroblastoma Therapy Consortium · NCT06450041Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodefic
Phase 1/Phase 2 · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT01306019Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06530576Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07510815Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07283679Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paedia
EARLY_Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07283315Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients
Phase 1 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07366658An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06693973Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognosticat
Phase N/A · 1 location(s) · National Taiwan University Hospital · NCT06678724A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Stud
Phase 1 · 1 location(s) · Medigen Biotechnology Corporation · NCT05394714A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Phase 1 · 9 location(s) · Memorial Sloan Kettering Cancer Center · NCT05010005"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL
Phase 1/Phase 2 · 1 location(s) · Mingzhi Zhang · NCT06559553The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Phase 1/Phase 2 · 11 location(s) · AVM Biotechnology Inc · NCT04329728Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07589530Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
Phase 1/Phase 2 · 1 location(s) · Aibin Liang，MD，Ph.D. · NCT05842707Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Phase 2 · 10 location(s) · Memorial Sloan Kettering Cancer Center · NCT02974647Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Vir
Phase 4 · 1 location(s) · Beijing Children's Hospital · NCT07029958Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07641023A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
Phase 1/Phase 2 · 19 location(s) · Nkarta, Inc. · NCT06557265Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Che
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06383572Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recu
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT06660420PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma
NA · 1 location(s) · Ruijin Hospital · NCT05662540Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07627698Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06824883Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07480928NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Phase 1/Phase 2 · 1 location(s) · Nationwide Children's Hospital · NCT04211675A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT04365036Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refr
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT07072234
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.